Objective. To examine the potential immunologic mechanism and involvement of antiphos pholipid antibodies in the pathogenesis of heart valve lesions in patients with the antiphos pholipid syndrome (APS).
Methods. Immunoperoxidase and immunofluorescence staining methods were used to evaluate 13 heart valve specimens derived from eight patients with the APS, either primary or secondary to systemic lupus erythematosus. Primary antibodies to human immuno globulins, complement components, serum albumin and a monoclonal anti-idiotypic anti body to human anticardiolipin antibodies (aCL) were employed. Various tissue specimens from a patient with the APS as well as deformed and normal valves from subjects without the APS were used as controls.
Results. Linear subendothelial deposition consisting of immunoglobulins with complement components but not of a non-specific serum protein was found in deformed valves from patients with the APS. None of the control valves or tissues disclosed similar deposition. The same pattern and location of staining was obtained by the anti-idiotypic antibody to aCL. A significant amount of IgG immunoglobulins that bound to cardiolipin was eluted from a valve of a patient with secondary APS.
Conclusion. Deposits of immunoglobulins including aCL, and of complement components, are common in affected valves of patients with primary and secondary APS. Such deposits may be involved in the pathogenesis of valvular lesions.
Libman E., Sacks B.A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med1924; 33: 701-737.
2.
Gross L.The cardiac lesion in Libman-Sacks disease with a consideration of its relationship to acute diffuse lupus erythematosus. Am J Pathol1940; 16: 375-408.
3.
Klinkhoff AV et al. M-mode and two-dimensional echocardiographic abnormalities in systemic lupus erythematosus. JAMA1985; 253: 3273-3277.
4.
Doherty NE et al. Echocardiographic findings in systemic lupus erythematosus. Am J Cardiol1988; 61: 1144.
5.
Galve E. et al. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med1988; 319: 817-823.
6.
Nihoyannopoulos P. et al. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation1990; 82: 369-375.
7.
Cervera R. et al. Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis1992; 51: 156-159.
8.
Guinta A. et al. Spectrum of cardiac involvement in systemic lupus erythematosus: echocardiographic, echo-doppler observations and immunological investigations . Acta Cardiol1993; 48: 183-197.
9.
Straaton KV et al. Clinically significant valvular heart disease in systemic lupus erythematosus. Am J Med1988; 85: 645-650.
10.
Chartash EK et al. Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome . Am J Med1989; 86: 407-412.
11.
Khamashta MA et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet1990; 335: 1541-1544.
12.
Crozier IG et al. Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol1990; 65: 1145-1148.
13.
Bulkley BH, Roberts WC: The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. Am J Med1975; 58: 243-264.
14.
Shearn MA: The heart in systemic lupus erythematosus: a review. Am Heart J1959; 58: 452-466.
15.
Durack DT: Experimental bacterial endocarditis: 4. Structure and evolution of very early lesions. J Pathol1975; 115: 81-89.
16.
Asherson RA , Hughes Grv: The expanding spectrum of Libman Sacks endocarditis: the role of anti-phospholipid antibodies. Clin Exp Rheum1989; 7: 225-228.
17.
Shapiro RF et al. Immunopathogenesis of Libman-Sacks endocarditis. Ann Rheum Dis1977; 36: 508-516.
18.
Gomez P. et al. Association between cardiac abnormalities and raised anticardiolipin antibodies in systemic lupus erythematosus. Postgrad Med J1988; 64: 723.
19.
Leung WH et al. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med1990; 89: 411-419.
20.
Metz D. et al. Prevalence of valvular involvement in systemic lupus erythematosus and association with antiphospholipid syndrome: a matched echocardiographic study. Cardiology1994; 85: 129-136.
21.
Barbut D. et al. Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. Cardiology1991; 79: 99-109.
22.
Asherson RA , Cervera R.: The antiphospholipid syndrome: a syndrome in evolution. Ann Rheum Dis1992 ; 51: 147-150.
23.
Brenner B. et al. Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol1991; 18: 931-936.
24.
Cervera R. et al. High prevalence of significant heart valve lesions in patients with the 'primary' antiphospholipid syndrome. Lupus1991; 1: 43-47.
25.
Galve E. et al. Valvular heart disease in the primary antiphospholipid syndrome . Ann Intern Med1992; 116: 293-298.
Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum1982; 25: 1271-1277.
28.
Sutjita M. et al. A common anti-cardiolipin antibody idiotype in autoimmune disease: identification using a mouse monoclonal antibody directed against a naturally-occurring anti-phospholipid antibody. Clin Exp Immunol1989; 75: 211-216.
29.
Sutjita M. et al. Polyspecific human and murine antibodies to diphteria and tetanus toxoids and phospholipids. Clin Exp Immunol1988; 73: 191-197.
30.
Bakimer R. et al. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest1992; 89: 1558-1663.
31.
Blank M. et al. Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate. Clin Exp Immunol1994; 98: 434-441.
32.
Hojnik M. et al. Anticardiolipin antibodies in infections are heterogeneous in their dependency on β2-glycoprotein I: analysis of anticardiolipin antibodies in leprosy. Lupus1994; 3: 515-521.
33.
Bidani AK et al. Immunopathology of cardiac lesions in fatal systemic lupus erythematosus . Am J Med1980; 69: 849-858.
34.
Merz H. et al. Constant detection of surface and cytoplasmic immunoglobulin heavy and light chain expression in formalin-fixed and paraffin-embedded material . J Pathol1993; 170: 257-264.
35.
D'Alton JG et al. Multiple transient ischemic attacks, lupus anticoagulant and verrucous endocarditis. Stroke1985; 16: 512-514.
36.
Roldan CA et al. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol1992; 20: 1127-1134.
37.
Gleason CB et al. A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome vs anticardiolipin-negative systemic lupus erythematosus . Am Heart J1993; 25: 1123-1129.
38.
Koike T., Tomioka H., Kumagai A.: Antibodies cross-reactive with DNA and cardiolipin in patients with systemic lupus erythematosus. Clin Exp Immunol1982 ; 50: 298-302.
39.
McNeil HP et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA1990; 87: 4120-4124.
40.
Roubey Ras et al. 'Anticardiolipin' autoantibodies recognize β2glycoprotein I in the absence of phospholipid. J Immunol1995; 154: 954-960.
41.
Brey RL, Coull BM: Antiphospholipid antibodies: origin, specificity and mechanism of action. Stroke1992; 23: 15-18.
42.
Hasselaar P. et al. Crossreactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. Thromb Haemostas1990; 63: 169-173.
43.
McGrae KR et al. Detection of endothelial cell reactive immunoglobulin in patients with antiphospholipid antibodies. Br J Haematol1991; 79: 595-605.
44.
Cervera R. et al. Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. Autoimmunity1991; 11: 1-6.
45.
Galli M., Bevers EM: Inhibition of phospholipid-dependent coagulation reactions by 'antiphospholipid antibodies': possible modes of action. Lupus1994; 3: 223-228.
46.
Ford SE et al. Thrombotic endocarditis and lupus anticoagulant. Arch Pathol Lab Med1989; 113: 350-353.
47.
Escolar G. et al. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Studies in a perfusion system. Arterioscler Thromb1992; 12: 196—200.
48.
Kornberg A. et al. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol1994; 153: 1328-1332.
49.
Oosting JD et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism. Blood1993; 81: 2618-2625.
